Get started
Work

204P Clinical features predictive of never-progressive disease to first-line anti-HER2 therapy: Real-world data from the ESME national cohort

Year: 2024
Type: article
Abstract: First-line (1L) anti-HER2 therapy has dramatically improved survival for patients (pts) with HER2+ metastatic breast cancer (MBC). We investigated clinicopathologic predictors of never progressive disease (PD) in the multicenter, real-world ESME-MBC cohort (NCT03275311).
Source: ESMO Open
DOI: 10.1016/j.esmoop.2024.103226
Authors: T. Grinda, M. Carton, S. Morganti, A. Mailliez, C. Levy, T. Petit, T. Bachelot, M. Arnedos, V.C. Dieras, V. Massard, F. Dalenc, I. Desmoulins, A. Gonçalves, C. Bailleux, J-S. Frenel, L. Bosquet, S. Delaloge, N.U. Lin, W. Jacot, H.A. Parsons
Institutions: Institut Gustave Roussy, Institut Curie, Dana-Farber Cancer Institute, Centre Oscar Lambret, Centre François Baclesse, Institut Strauss, Centre Léon Bérard, Institut Bergonié, Centre Eugène Marquis, Institut de Cancérologie de Lorraine, Institut Claudius Regaud, Centre Georges François Leclerc, Institut Paoli-Calmettes, Centre Antoine Lacassagne, Institut de Cancérologie de l'Ouest, UniCancer Group, Institut Regional du Cancer de Montpellier
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,730
Funder: AstraZeneca
OpenAlex ID: W4397006996
FWCI:
Cites: 1
Cited by:
Related to: 10